{
  "docId": "019de073-dba4-758b-bcbe-08ad83e87d71",
  "docSlug": "afc13b14322819221680611098a4aee7",
  "documentTitle": "Third Harmonic Bio | Investor Presentation Deck | 20 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 20,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 64,
  "notes": "MAD = Multiple Ascending Dose; SAE = Serious Adverse Event; AE = Adverse Event; ANC = Absolute Neutrophil Count; PBO = Placebo.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-dba4-758b-bcbe-08ad83e87d71/11",
  "deckHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71",
  "deckJsonHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71.json",
  "deckAnchorHref": "/decks/019de073-dba4-758b-bcbe-08ad83e87d71#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.33,
        "x": 0.035,
        "y": 0.25
      },
      "kind": "list",
      "text": "No dose escalation or study stopping criteria met; No clinically significant trends in chemistries, vital signs or ECGs observed; No SAEs reported; 3 moderate AEs reported, 1 that led to discontinuation; 1 mild AE reported that led to discontinuation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbb4cf0f-2a7c-4347-b2a8-6767a76ef7a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.63,
        "x": 0.365,
        "y": 0.208
      },
      "kind": "table",
      "text": "MAD Treatment Emergent Adverse Events table showing Preferred Terms and n/% for 200mg QD, 200mg BID, 500mg QD FED, 400mg BID, and PBO groups.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13a3dfdc-5893-40b5-b6f3-1964affb9e3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.396,
        "x": 0.035,
        "y": 0.065
      },
      "kind": "title",
      "text": "THB001 MAD Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23706072-1c62-4118-8406-24bf7b68c2dd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "45cf8a86-de32-4d74-8704-aa8f3cd45c24",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 provide data and results on THB001, including its ability to inhibit mast cell activity",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}